CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 54 enrolled
Drug / intervention
acyclovir/hydrocortisone creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01574612
NCT01574612Phase 3Completed

An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children

Meda Pharmaceuticals·interventional·Posted Apr 10, 2012·Updated May 22, 2014

In Brief

A Phase 3 clinical trial evaluating acyclovir/hydrocortisone cream for Herpes Labialis. Completed, enrolled 54 participants across 10 sites.

Detailed Summary

To test the safety of Xerese (acyclovir and hydrocortisone)Cream 5%/1% for the treatment of recurrent cold sores in children ages 6-11yrs after 5 days of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Labialis
CountriesUnited States
CollaboratorsTKL Research, Inc.

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 10, 2012
Enrollment StartMar 1, 2012
Primary CompletionDec 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.2 years ago

Interventions

acyclovir/hydrocortisone creamdrug

cream applied topically to lesion five times daily for five days